Insmed said FY 2025 total revenues were USD 606.4 million (+67%), including ARIKAYCE revenues of USD 433.8 million (+19%) and BRINSUPRI revenues of USD 172.7 million. In Q4 2025, total revenues were USD 263.8 million (+153%), with ARIKAYCE at USD 119.2 million (+14%) and BRINSUPRI at USD 144.6 million (following its U.S. commercial launch in August 2025). Q4 2025 net loss was USD 328.5 million, or USD 1.54 per share, and FY 2025 net loss was USD 1.28 billion, or USD 6.42 per share; Q4 2025 R&D expenses were USD 254.9 million and SG&A expenses were USD 212.5 million, while FY 2025 R&D was USD 771.1 million and SG&A was USD 701.2 million. Insmed ended 2025 with approximately USD 1.4 billion in cash, cash equivalents and marketable securities. For 2026, Insmed forecast BRINSUPRI revenues of at least USD 1.0 billion and reiterated ARIKAYCE revenue guidance of USD 450 million to USD 470 million. The company said the European Commission approved BRINSUPRI for non-cystic fibrosis bronchiectasis in patients aged 12 and older, and it expects regulatory decisions in the UK and Japan in 2026. Insmed also said it expects a Phase 3 ENCORE topline readout for ARIKAYCE in March or April 2026 and, pending positive data, plans an sNDA in the second half of 2026 for MAC lung disease label expansion in the U.S., alongside discussions with Japan’s PMDA. Separately, the FDA granted orphan drug designation to treprostinil palmitil for PAH; Insmed plans to initiate a Phase 3 TPIP study in PAH in the first half of 2026 and expects TPIP Phase 2b open-label extension data in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602190700PR_NEWS_USPR_____NY90788) on February 19, 2026, and is solely responsible for the information contained therein.